ETER-MED Sp. z o.o. is a Polish medical technology developer based in Gdańsk, with a dedicated R&D Centre in Straszyn. The company pairs a clinical care base with in-house device development, giving direct access to the patient populations it designs for.
R&D runs on two technology platforms:
AI-guided cryotherapy. CRYO-AI develops an ultrasound-guided cryoanalgesia system with disposable echogenic cryoprobes for non-opioid pain management. The work combines laser-micromachined probe surfaces, physics-informed neural networks for real-time ice-ball prediction, and deep-learning nerve segmentation. Target: CE-marked Class IIb AI medical device.
Ozone-based wound therapy. A portfolio of devices and formulations for chronic and hard-to-heal wounds — ozonated-water hydrosurgical debridement using SL-DBD plasma electrodes, semi-automated ozone autohemotherapy for diabetic foot syndrome, and ozonide-based active substances.
ETER-MED acts as coordinator and consortium partner across Eurostars, Polish national programmes (NCBiR/FENG, PARP, ABM) and regional EFRR funding, working with international R&D partners including CSEM (Switzerland). Development is run under EU MDR from concept, with parallel FDA 510(k) pathways where relevant.
A Polish medtech SME and healthcare provider offering a ready device-based intervention for diabetic foot syndrome, together with its own clinical site, patient recruitment and MDR regulatory capability.
Partner seeks Consortium/Coordinator
Consortium/Coordinator seeks Partners
Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
Author
R&D Engineer at Niepubliczy Zakład Opieki Zdrowotnej ETER-MED
A Polish outpatient site offering patient recruitment and trial conduct in chronic wound care, diabetic foot and pain management, with in-house regulatory authoring for device clinical investigations under EU MDR and ISO 14155.
Partner seeks Consortium/Coordinator
Consortium/Coordinator seeks Partners
Digital health and AI: HORIZON-HLTH-2027-03-TOOL-08 Towards Artificial General Intelligence (AGI) for healthcare
Clinical trials: HORIZON-HLTH-2027-02-DISEASE-01-two-stage Innovative healthcare interventions for non-communicable diseases
Clinical trials: HORIZON-HLTH-2027-02-DISEASE-14-two-stage Clinical trials for advancing innovative interventions for neurodegenerative diseases
Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
Digital health and AI: HORIZON-HLTH-2027-02-TOOL-01-two-stage Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Author
R&D Engineer at Niepubliczy Zakład Opieki Zdrowotnej ETER-MED
ETER-MED offers AI-guided cryoneurolysis as a non-pharmacological route to opioid de-escalation in patients on multiple medications, including cancer pain. We contribute the device, a clinical site and MDR expertise to a CARE-02 consortium.
Consortium/Coordinator seeks Partners
Digital health and AI: HORIZON-HLTH-2027-03-TOOL-08 Towards Artificial General Intelligence (AGI) for healthcare
Healthcare innovations: HORIZON-HLTH-2027-01-CARE-02 Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
Healthcare innovations: HORIZON-MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
Author
R&D Engineer at Niepubliczy Zakład Opieki Zdrowotnej ETER-MED